Mind Medicine (MindMed) Inc. (MMDCF) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Mind Medicine (MindMed) Inc. (MMDCF) trades at $0.0135 with AI Score 44/100 (Grade C). Mind Medicine (MindMed) Inc. is a biopharmaceutical company focused on developing psychedelic-inspired medicines. The company aims to address unmet needs in brain health disorders. Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 17, 2026Analyst Coverage for MMDCF: MMDCF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates MMDCF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
MMDCF: 2/3 scored disciplines lean bearish. Dominant signal: Jim Simons bearish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Mind Medicine (MindMed) Inc. (MMDCF) Healthcare & Pipeline Overview
Mind Medicine (MindMed) Inc. (MMDCF) is a biopharmaceutical company developing psychedelic-inspired therapies for brain health disorders. Operating in a high-risk, high-reward sector, MindMed focuses on innovative treatments, but faces regulatory hurdles and funding challenges in the competitive pharmaceutical landscape.
What Is the Investment Thesis for MMDCF?
MindMed presents a high-risk, high-reward investment opportunity within the emerging psychedelic medicine sector. The company's diverse pipeline of drug candidates targeting various brain health disorders offers significant potential upside if clinical trials are successful and regulatory approvals are obtained. However, the company's negative P/E ratio of -8.96 reflects its current lack of profitability and reliance on funding for research and development. Key value drivers include successful clinical trial outcomes, strategic partnerships, and regulatory milestones. Growth catalysts include the expanding acceptance of psychedelic therapies and increasing investment in mental health research. Potential risks include regulatory hurdles, clinical trial failures, and competition from established pharmaceutical companies.
Based on FMP financials and quantitative analysis
MMDCF Key Highlights
MindMed is focused on developing psychedelic-inspired medicines, a novel approach to treating brain health disorders.
- The company has a diverse pipeline of drug candidates targeting conditions such as anxiety, depression, ADHD, and addiction.
- MindMed's P/E ratio is -8.96, indicating that the company is currently not profitable.
- The company's beta of 2.36 suggests that the stock is more volatile than the market average.
- MindMed does not currently offer a dividend, reflecting its focus on reinvesting earnings into research and development.
Who Are MMDCF's Competitors?
MMDCF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| GCI Gannett Co., Inc. | $5.93 | -0.34% | $872M | 42 |
| LAZY Lazydays Holdings, Inc. | $5.34 | +0.00% | $77.1M | 41 |
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.00% | $196M | 77 |
| CGEN Compugen Ltd. | $2.65 | +8.61% | $251M | 76 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are MMDCF's Key Strengths?
Innovative approach to treating brain health disorders with psychedelic-inspired medicines.
- Diverse pipeline of drug candidates targeting various mental health conditions.
- Strategic partnerships with leading research institutions and healthcare providers.
- First-mover advantage in the emerging psychedelic medicine sector.
What Are MMDCF's Weaknesses?
High reliance on funding for research and development.
- Negative P/E ratio indicating current lack of profitability.
- Regulatory hurdles and clinical trial risks.
- Limited commercialization experience.
What Could Drive MMDCF Stock Higher?
Clinical trial results for MM-120 in generalized anxiety disorder.
- FDA feedback on Phase 3 trial design for lead compound.
- Expansion of research collaborations with academic institutions.
- Increasing awareness and acceptance of psychedelic therapies.
- Advancements in drug delivery technologies for psychedelic medicines.
What Are the Key Risks for MMDCF?
Clinical trial failures or regulatory setbacks.
- Competition from established pharmaceutical companies.
- Changing public perception of psychedelic therapies.
- High reliance on funding for research and development.
- Volatility in the biotechnology sector.
What Are the Growth Opportunities for MMDCF?
- Expansion of Clinical Trials: MindMed has the opportunity to expand its clinical trials to new geographic regions and patient populations. This would allow the company to gather more data on the safety and efficacy of its drug candidates, potentially accelerating the regulatory approval process. The market for clinical trial services is estimated to be worth billions of dollars, offering significant growth potential for MindMed.
- Strategic Partnerships: MindMed can pursue strategic partnerships with other pharmaceutical companies, research institutions, and healthcare providers. These partnerships could provide access to new technologies, expertise, and distribution channels, enhancing the company's competitive position. The market for pharmaceutical partnerships is highly active, with numerous opportunities for collaboration and innovation.
- Regulatory Approvals: Obtaining regulatory approvals for its drug candidates is a critical growth driver for MindMed. Successful approvals would allow the company to commercialize its therapies and generate revenue. The regulatory approval process is rigorous and time-consuming, but the potential rewards are substantial, with blockbuster drugs generating billions of dollars in annual sales.
- New Drug Development: MindMed can invest in the development of new drug candidates targeting additional brain health disorders. This would expand the company's pipeline and diversify its revenue streams. The market for new drug development is highly competitive, but the potential for innovation and breakthrough therapies is significant.
- Increased Investment in Mental Health: The increasing awareness of mental health issues and growing investment in mental health research create a favorable environment for MindMed. This trend is driving demand for innovative therapies and attracting funding to companies in the psychedelic medicine sector. The market for mental health treatments is expected to continue to grow in the coming years, offering significant opportunities for MindMed.
What Are MMDCF's Competitive Advantages?
- Intellectual property protection through patents on its drug candidates.
- Proprietary research and development capabilities in the field of psychedelic medicine.
- Strategic partnerships with leading research institutions and healthcare providers.
- First-mover advantage in the emerging psychedelic medicine sector.
What Does MMDCF Do?
Mind Medicine (MindMed) Inc., also known as MindMed, is a biopharmaceutical company focused on discovering, developing, and deploying psychedelic-inspired medicines and therapies to address unmet medical needs. The company was founded with the vision of transforming the treatment landscape for brain health disorders by harnessing the potential of psychedelic substances. MindMed's research and development efforts are centered on a diverse pipeline of drug candidates, targeting conditions such as anxiety, depression, ADHD, and addiction. The company's approach involves rigorous scientific investigation, clinical trials, and strategic partnerships to advance its therapies through the regulatory approval process. MindMed aims to establish itself as a leader in the emerging field of psychedelic medicine, offering innovative solutions to improve patient outcomes and quality of life. The company's geographic reach is primarily focused on North America and Europe, where it conducts clinical trials and seeks regulatory approvals for its drug candidates. MindMed faces competition from other pharmaceutical companies and research institutions exploring psychedelic therapies, as well as established treatments for brain health disorders.
What Products and Services Does MMDCF Offer?
- Develop psychedelic-inspired medicines for brain health disorders.
- Conduct clinical trials to evaluate the safety and efficacy of drug candidates.
- Seek regulatory approvals for its therapies from health authorities.
- Establish strategic partnerships with other pharmaceutical companies and research institutions.
- Research and develop new drug candidates targeting various mental health conditions.
- Explore the therapeutic potential of psychedelic substances through scientific investigation.
- Aim to transform the treatment landscape for brain health disorders.
How Does MMDCF Make Money?
- Develop and patent novel psychedelic-inspired medicines.
- Conduct clinical trials to demonstrate safety and efficacy.
- Seek regulatory approval from agencies like the FDA.
- Commercialize approved therapies through partnerships or direct sales.
What Industry Does MMDCF Operate In?
MindMed operates within the rapidly evolving biotechnology industry, specifically focusing on psychedelic medicine. This sector is characterized by increasing interest in alternative treatments for mental health disorders and growing acceptance of psychedelic therapies. The competitive landscape includes other pharmaceutical companies and research institutions exploring psychedelic substances, as well as established treatments for brain health disorders. The market for mental health treatments is substantial, with significant unmet needs and increasing investment in research and development. MindMed aims to capitalize on these trends by developing innovative therapies and establishing itself as a leader in the psychedelic medicine field.
Who Are MMDCF's Key Customers?
- Patients suffering from brain health disorders such as anxiety, depression, ADHD, and addiction.
- Healthcare providers who prescribe and administer the company's therapies.
- Pharmaceutical companies and research institutions that collaborate with MindMed on drug development.
- Payers, including insurance companies and government healthcare programs, that reimburse the cost of the company's therapies.
Key Financial Metrics
Return on assets is -59.2%, showing how much profit it generates from its asset base. Its free cash flow yield is -3.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 4.69 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -4.9%, the inverse of the P/E and a quick read on earnings relative to price.
MMDCF Valuation & Market Position
Relative to its peer group, MMDCF's quantitative score of 44/100 is below the peer average of 63/100.
Company Profile
Mind Medicine (MindMed) Inc. operates in the Medical - Pharmaceuticals industry within the Healthcare sector. The company is led by CEO Robert Barrow.
MMDCF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future, indicating that key stakeholders believe in its growth potential.
- The growing interest in psychedelic therapies is gaining traction, positioning MindMed favorably within a burgeoning market.
- Positive community sentiment has emerged around recent product developments, with discussions highlighting innovative approaches to mental health.
- Increased media coverage and awareness of mental health solutions have amplified MindMed's visibility, attracting potential investors and partners.
Bear Case
- Concerns around regulatory hurdles for psychedelic substances could hinder the company's progress, creating uncertainty among investors.
- Some community members express skepticism about the scalability of MindMed's solutions, questioning their long-term viability in a competitive landscape.
- Recent social sentiment has shown mixed reviews on the effectiveness of MindMed's products, leading to hesitance among potential users and investors.
- Market perception remains cautious, with discussions reflecting fears of overvaluation and the potential for volatility in the sector.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
MMDCF Latest News
No recent news available for MMDCF.
MMDCF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for MMDCF.
Price Targets
Wall Street price target analysis for MMDCF.
MMDCF MoonshotScore
What does this score mean?
The MoonshotScore rates MMDCF 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Robert Barrow
CEO
Robert Barrow serves as the CEO of Mind Medicine (MindMed) Inc. His background includes extensive experience in the pharmaceutical industry, with a focus on drug development and commercialization. Prior to joining MindMed, Barrow held leadership positions at various biotechnology companies, where he oversaw clinical trials, regulatory submissions, and product launches. His expertise spans multiple therapeutic areas, including neuroscience and mental health. Barrow's educational credentials include advanced degrees in pharmacology and business administration.
Track Record: Under Robert Barrow's leadership, MindMed has advanced its pipeline of psychedelic-inspired medicines and achieved key milestones in clinical development. He has focused on building strategic partnerships and securing funding to support the company's research and development efforts. Barrow has also overseen the expansion of MindMed's clinical trial programs and the preparation of regulatory submissions for its drug candidates. His strategic decisions have positioned MindMed as a leader in the emerging field of psychedelic medicine.
MMDCF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that MindMed may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure, potentially increasing investment risk. Trading on the OTC Other market typically involves less stringent listing requirements compared to major exchanges like the NYSE or NASDAQ, which demand higher levels of transparency and corporate governance.
- OTC Tier: OTC Other
- Limited financial disclosure due to the OTC Other tier.
- Lower trading volume and liquidity compared to major exchanges.
- Potential for wider bid-ask spreads and increased trading costs.
- Higher risk of fraud or manipulation due to less stringent regulatory oversight.
- Shell Risk: Detected
- Verify the company's financial statements and SEC filings (if available).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's legal and regulatory compliance.
- Monitor trading volume and bid-ask spreads for liquidity.
- Check for any red flags or warning signs of potential fraud or manipulation.
- Presence of a professional management team.
- Active research and development efforts in the psychedelic medicine sector.
- Strategic partnerships with reputable research institutions.
- Positive clinical trial results for its drug candidates.
- Focus on addressing unmet medical needs in brain health disorders.
What Investors Ask About Mind Medicine (MindMed) Inc. (MMDCF) — Healthcare
What does the AI Score mean for MMDCF?
MMDCF holds an AI Score of 44/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. Mind Medicine (MindMed) Inc. is a biopharmaceutical company focused on developing psychedelic-inspired medicines. The company aims to address unmet needs in brain health disorders.
What does Mind Medicine (MindMed) Inc. do?
Mind Medicine (MindMed) Inc. is a biopharmaceutical company focused on discovering, developing, and deploying psychedelic-inspired medicines and therapies to address unmet medical needs in brain health disorders. The company's pipeline includes drug candidates targeting conditions such as anxiety, depression, ADHD, and addiction. MindMed aims to transform the treatment landscape for mental health by harnessing the therapeutic potential of psychedelic substances through rigorous scientific investigation and clinical trials.
What are the main risks for MMDCF?
The main risks for MindMed include clinical trial failures, regulatory setbacks, and competition from established pharmaceutical companies. The company's reliance on funding for research and development also poses a risk, as any difficulty in securing financing could impact its ability to advance its pipeline.
What are the key factors to evaluate for MMDCF?
Mind Medicine (MindMed) Inc. (MMDCF) holds an AI score of 44/100 (low). MindMed presents a high-risk, high-reward investment opportunity within the emerging psychedelic medicine sector. Not financial advice.
How frequently does MMDCF data refresh on this page?
MMDCF's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven MMDCF's recent stock price performance?
Mind Medicine (MindMed) Inc. (MMDCF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative approach to treating brain health disorders with psychedelic-inspired medicines. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider MMDCF overvalued or undervalued right now?
Mind Medicine (MindMed) Inc. (MMDCF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research MMDCF before investing?
Before investing in Mind Medicine (MindMed) Inc. (MMDCF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding MMDCF to a portfolio?
Key strength of Mind Medicine (MindMed) Inc. (MMDCF): Innovative approach to treating brain health disorders with psychedelic-inspired medicines. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- AI analysis is pending for MMDCF.